These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 28890238)
1. Delivering the right message: Challenges and opportunities in lipid nanoparticles-mediated modified mRNA therapeutics-An innate immune system standpoint. Granot Y; Peer D Semin Immunol; 2017 Dec; 34():68-77. PubMed ID: 28890238 [TBL] [Abstract][Full Text] [Related]
2. Arrayed CRISPR Screening Identifies Novel Targets That Enhance the Productive Delivery of mRNA by MC3-Based Lipid Nanoparticles. Ross-Thriepland D; Bornot A; Butler L; Desai A; Jaiswal H; Peel S; Hunter MR; Odunze U; Isherwood B; Gianni D SLAS Discov; 2020 Jul; 25(6):605-617. PubMed ID: 32441189 [TBL] [Abstract][Full Text] [Related]
3. Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes. Veiga N; Goldsmith M; Granot Y; Rosenblum D; Dammes N; Kedmi R; Ramishetti S; Peer D Nat Commun; 2018 Oct; 9(1):4493. PubMed ID: 30374059 [TBL] [Abstract][Full Text] [Related]
4. Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals. Thess A; Grund S; Mui BL; Hope MJ; Baumhof P; Fotin-Mleczek M; Schlake T Mol Ther; 2015 Sep; 23(9):1456-64. PubMed ID: 26050989 [TBL] [Abstract][Full Text] [Related]
5. Lipid nanoparticles-loaded with toxin mRNA represents a new strategy for the treatment of solid tumors. Granot-Matok Y; Ezra A; Ramishetti S; Sharma P; Naidu GS; Benhar I; Peer D Theranostics; 2023; 13(11):3497-3508. PubMed ID: 37441597 [No Abstract] [Full Text] [Related]
6. Advances in RNAi therapeutic delivery to leukocytes using lipid nanoparticles. Ramishetti S; Landesman-Milo D; Peer D J Drug Target; 2016 Nov; 24(9):780-786. PubMed ID: 27030014 [TBL] [Abstract][Full Text] [Related]
7. Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles. Yanez Arteta M; Kjellman T; Bartesaghi S; Wallin S; Wu X; Kvist AJ; Dabkowska A; Székely N; Radulescu A; Bergenholtz J; Lindfors L Proc Natl Acad Sci U S A; 2018 Apr; 115(15):E3351-E3360. PubMed ID: 29588418 [TBL] [Abstract][Full Text] [Related]
9. Unlocking Delivery Strategies for mRNA Therapeutics. Luo Z; Chen Y Recent Pat Anticancer Drug Discov; 2024; 19(2):126-129. PubMed ID: 37287306 [TBL] [Abstract][Full Text] [Related]
10. Recent advances in lipid nanoparticles for delivery of nucleic acid, mRNA, and gene editing-based therapeutics. Mukai H; Ogawa K; Kato N; Kawakami S Drug Metab Pharmacokinet; 2022 Jun; 44():100450. PubMed ID: 35381574 [TBL] [Abstract][Full Text] [Related]
11. Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery. Kowalski PS; Rudra A; Miao L; Anderson DG Mol Ther; 2019 Apr; 27(4):710-728. PubMed ID: 30846391 [TBL] [Abstract][Full Text] [Related]
12. Chemical modifications on siRNAs avoid Toll-like-receptor-mediated activation of the hepatic immune system in vivo and in vitro. Broering R; Real CI; John MJ; Jahn-Hofmann K; Ickenstein LM; Kleinehr K; Paul A; Gibbert K; Dittmer U; Gerken G; Schlaak JF Int Immunol; 2014 Jan; 26(1):35-46. PubMed ID: 24065781 [TBL] [Abstract][Full Text] [Related]
13. Pieter Cullis' quest for a lipid-based, fusogenic delivery system for nucleic acid therapeutics: success with siRNA so what about mRNA? Tam YK; Madden TD; Hope MJ J Drug Target; 2016 Nov; 24(9):774-779. PubMed ID: 27588674 [TBL] [Abstract][Full Text] [Related]
14. Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles. Cohen ZR; Ramishetti S; Peshes-Yaloz N; Goldsmith M; Wohl A; Zibly Z; Peer D ACS Nano; 2015 Feb; 9(2):1581-91. PubMed ID: 25558928 [TBL] [Abstract][Full Text] [Related]
15. A Nanoprimer To Improve the Systemic Delivery of siRNA and mRNA. Saunders NRM; Paolini MS; Fenton OS; Poul L; Devalliere J; Mpambani F; Darmon A; Bergère M; Jibault O; Germain M; Langer R Nano Lett; 2020 Jun; 20(6):4264-4269. PubMed ID: 32357299 [TBL] [Abstract][Full Text] [Related]
16. Microfluidic Production and Application of Lipid Nanoparticles for Nucleic Acid Transfection. Thomas A; M Garg S; De Souza RAG; Ouellet E; Tharmarajah G; Reichert D; Ordobadi M; Ip S; Ramsay EC Methods Mol Biol; 2018; 1792():193-203. PubMed ID: 29797261 [TBL] [Abstract][Full Text] [Related]
17. Altering the immune response with lipid-based nanoparticles. Landesman-Milo D; Peer D J Control Release; 2012 Jul; 161(2):600-8. PubMed ID: 22230342 [TBL] [Abstract][Full Text] [Related]
18. Overcoming analytical challenges to generate data critical to understanding lipid nanoparticle-delivered modified mRNA biodistribution. Hawthorne G; Henderson N; Hölttä M; Khan S; Lindqvist J; Wilson A Bioanalysis; 2019 Nov; 11(21):1993-2001. PubMed ID: 31617402 [No Abstract] [Full Text] [Related]
19. Rational design of anti-inflammatory lipid nanoparticles for mRNA delivery. Zhang H; Han X; Alameh MG; Shepherd SJ; Padilla MS; Xue L; Butowska K; Weissman D; Mitchell MJ J Biomed Mater Res A; 2022 May; 110(5):1101-1108. PubMed ID: 35076171 [TBL] [Abstract][Full Text] [Related]
20. Stabilization of Ostwald ripening in low molecular weight amino lipid nanoparticles for systemic delivery of siRNA therapeutics. Gindy ME; Feuston B; Glass A; Arrington L; Haas RM; Schariter J; Stirdivant SM Mol Pharm; 2014 Nov; 11(11):4143-53. PubMed ID: 25317715 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]